Experimental drug

  • Otonomy's ear drug fails mid-stage trial, shares slide

    (Reuters) - Otonomy Inc said its experimental drug did not meet the main goal of reducing the incidence of vertigo in a mid-stage trial in patients suffering from Ménière's disease. The company's shares, listed on the Nasdaq in August last year, fell 16 percent to $26.00 in extended trading on…

    Reuters